Secretory Carcinoma of the Breast: A Rare Entity With Favorable Prognosis

TL;DR

Secretory breast carcinoma is a rare type of breast cancer with a good prognosis, but there is no agreed-upon treatment due to its rarity.

Contribution

The paper presents a case study and literature review to highlight the clinical features and management of secretory breast carcinoma.

Findings

SBC is rare and has a favorable prognosis despite being triple-negative or hormone receptor-low.

Treatment options are not well-defined, with surgery and radiotherapy being commonly used.

Chemotherapy and hormone therapy efficacy remains unexplored in SBC.

Abstract

Secretory breast carcinoma (SBC) is an extremely rare entity of breast cancer, which can affect all age groups. The diagnosis is based on the characteristic microscopic appearance, and despite the triple negativity or low hormone receptor positivity, SBC is generally characterized by a favorable prognosis.

Due to the rarity of the disease, no clear consensus on optimal treatment is available. Nevertheless, conservative surgery or mastectomy is the main therapeutic option. The efficacy of chemotherapy, radiotherapy, and hormone therapy in this pathology has not been rigorously explored. We report the case of a 65-year-old woman with SBC treated with surgery and adjuvant radiotherapy, with a review of the literature.

Figures